Trial · NCT07886047
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
NCT07886047, Phase 1, Recruiting, Second Xiangya Hospital of Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer. Trials, record NCT07886047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- NCT number
- NCT07886047
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 18 participants, estimated
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Propranolol Hydrochloride, Adebrelimab, Chemotherapy
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) in the Extensive-Stage SCLC Cohort | Through study completion, up to 24 months. | Objective response rate is defined as the proportion of participants with extensive-stage small cell lung cancer who achieve a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. |
| Primary | Disease Control Rate (DCR) in the Extensive-Stage SCLC Cohort | Through study completion, up to 24 months. | Disease control rate is defined as the proportion of participants with extensive-stage small cell lung cancer who achieve a best overall response of complete response (CR), partial response (PR), or stable disease (SD), as assessed by investigators according to RECIST version 1.1. |
| Primary | Incidence and Severity of Treatment-Emergent Adverse Events in the Extensive-Stage SCLC Cohort | Through study completion, up to 24 months. | Safety will be evaluated by the number and percentage of participants experiencing treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and immune-related adverse events (irAEs). Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
| Primary | R0 Resection Rate in the Resectable Early-Stage SCLC Cohort | Perioperative | The R0 resection rate is defined as the proportion of participants scheduled for surgery who successfully undergo complete surgical resection with microscopically negative margins (R0) following neoadjuvant treatment with propranolol hydrochloride, adebrelimab, and platinum-based chemotherapy. |
| Primary | Incidence and Severity of Treatment-Related Adverse Events and Perioperative Complications in the Resectable Early-Stage SCLC Cohort | Through study completion, up to 12 months. | The incidence and severity of treatment-related adverse events and perioperative complications will be assessed in participants with resectable early-stage small cell lung cancer (SCLC). Safety during neoadjuvant therapy will be evaluated based on adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events (irAEs), with severity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Perioperative complications will be assessed based on the occurrence and severity of intraoperative and postoperative complications, including perioperative mortality. |
| Secondary | Progression-Free Survival (PFS) in the Extensive-Stage SCLC Cohort | Through study completion, up to 24 months. | Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression, as assessed by investigators according to RECIST version 1.1, or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Through study completion, up to 24 months. | Overall survival is defined as the time from the first dose of study treatment to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive. |
| Secondary | Pathological Complete Response (pCR) Rate in the Resectable Early-Stage SCLC Cohort | Perioperative | Pathological complete response is defined as the absence of residual viable tumor cells in the resected primary tumor and regional lymph nodes (ypT0N0) following neoadjuvant treatment. The pCR rate is calculated as the proportion of participants achieving pCR among those who undergo surgical resection. |
| Secondary | Major Pathological Response (MPR) Rate in the Resectable Early-Stage SCLC Cohort | Perioperative | Major pathological response is defined as 10% or less residual viable tumor cells in the resected primary tumor following neoadjuvant treatment. The MPR rate is calculated as the proportion of participants achieving MPR among those who undergo surgical resection. |
| Secondary | Disease-Free Survival (DFS) in the Resectable Early-Stage SCLC Cohort | Through study completion, up to 12 months. | Disease-free survival is defined as the time from surgical resection to the first occurrence of disease recurrence, a second primary malignancy, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last adequate disease assessment. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886047
GET https://conductscience.org/api/trials/v1/NCT07886047/registered